How Common Is ME/CFS? Prevalence in Europe

A Continent-Wide Blind Spot

Ask any epidemiologist how many people in Europe are living with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and you will get a frustrating answer: nobody knows. Not really. Study after study has been conducted at the national level — a Swedish cohort here, a British survey there — but no one has yet stitched those threads into a coherent picture of the illness across Europe as a whole. The true prevalence and incidence of ME/CFS across the continent remains, in the language of science, unknown.

This is not a trivial gap. ME/CFS is a serious, complex, biological illness affecting multiple body systems. It causes profound, debilitating fatigue that rest does not relieve, post-exertional malaise (a worsening of symptoms following even minor physical or mental effort), unrefreshing sleep, cognitive impairment — the disorienting mental fog that patients describe as thinking through treacle — and, frequently, orthostatic intolerance, where simply sitting up or standing triggers dizziness. People with ME/CFS are not tired in any ordinary sense; many are housebound or bedbound, and the condition can persist for years or decades. Without knowing how many people are affected across Europe, healthcare systems cannot plan services, researchers cannot secure funding on the scale the illness demands, and policymakers cannot act with the urgency the situation requires.

Enter EUROMENE

The European Network on ME/CFS (EUROMENE) exists precisely to confront these gaps. Bringing together researchers and clinicians from across the continent, EUROMENE is undertaking a systematic review of European literature — the most rigorous continent-wide attempt yet to produce a robust, evidence-based summary of how common ME/CFS actually is across member countries.

The design of the review is deliberately thorough. Researchers conduct structured searches across three major academic databases — PubMed, Scopus, and Web of Science — with no language restrictions applied. That last detail matters more than it might seem: a great deal of European epidemiological research is published in languages other than English, and excluding it would skew the findings towards countries with stronger traditions of English-language publication, leaving places like Portugal, Hungary, or Romania underrepresented. Every eligible study is handled by two independent reviewers who search, screen, select, and extract data, then resolve any disagreements by consensus — a standard safeguard against individual bias shaping the conclusions.

Going Beyond the Databases

Even the most exhaustive database search has limits. Academic databases index what is formally published; they miss data sitting in national registers, government health statistics, or reports circulated only in regional health systems. To close this further gap, EUROMENE researchers take two additional steps.

The first is citation checking: working both backward — tracing the references cited inside included studies — and forward, tracking how those studies have been cited by later work. This is a reliable method for surfacing relevant research that might otherwise slip through.

The second is grey-literature outreach. EUROMENE members across participating countries are contacted directly and asked to contribute prevalence and incidence figures from national registers or publications in their own languages that never made it into the major databases. This is, in effect, a human network functioning as a search engine for data that algorithms cannot reach — and for a condition as under-resourced as ME/CFS, it could prove to be among the most valuable parts of the entire exercise.

Rigour Under Difficult Conditions

Systematic reviews are only as trustworthy as the quality of their methods, and the EUROMENE team has taken methodological quality seriously. Study quality is assessed using the Joanna Briggs Institute Checklist for Prevalence Studies, a well-validated tool specifically designed for this type of epidemiological work. Crucially, the checklist is calibrated by six team members before it is applied to any study — a process that aligns judgements across reviewers and reduces the risk of inconsistency. Data are managed using Mendeley Desktop, and the information extracted from each study includes the research design, the country or region involved, the diagnostic criteria used to identify ME/CFS, and the characteristics of the study population.

That last point — diagnostic criteria — is where things become complicated, and where the review's authors are admirably candid about the limitations they face. ME/CFS has been defined by a number of different sets of criteria over the decades: the Fukuda criteria published in 1994, the Canadian Consensus Criteria from 2003, and the International Consensus Criteria from 2011, among others. Each captures the illness somewhat differently, and a patient who meets one set of criteria may not meet another. If European studies have used different definitions, comparing their numbers is like measuring the same room with rulers of different lengths. Because the available studies are expected to be few, and potentially heterogeneous in their methods, the review team presents findings as a narrative summary rather than forcing the data into a meta-analysis it may not support. Whether a formal meta-analysis is even feasible is evaluated separately at EUROMENE meetings — a considered, honest approach to scientific uncertainty.

No ethical approval is required for the review, since it draws only on publicly available data. Findings are intended to be published in peer-reviewed journals, presented at scientific conferences, and — importantly — communicated directly to policymakers, healthcare providers, and patient communities who need the information most.

Why This Work Matters

The strengths of this review are real: a carefully designed search strategy with explicit inclusion and exclusion criteria, no language restriction that might silence non-English-speaking countries, and active outreach to reduce the publication bias that so often shapes what science appears to know. These are not cosmetic features; they represent genuine methodological care in service of a question with significant human consequences.

The limitations are equally real, and the team does not hide them. Relatively few eligible European studies may exist. High variability across countries and diagnostic criteria may constrain how far comparisons can be pushed. The prevalence of ME/CFS across Europe as a whole is, even now, still unknown — and that is precisely the gap this work is designed to fill.

For the millions of people across the continent who live with ME/CFS — and for the clinicians, carers, and advocates who stand beside them — work like this is not abstract. Every robust data point is an argument for resources, recognition, and research. Getting the numbers right is where that argument begins.